PROVECTUS BIOPHARMS (PVCT)
PVCT moved a median of +0.01% 30 minutes after news, and +0.47% by the close. How PVCT actually reacts to news — the realized, point-in-time move the market made, measured across 220 labeled events over the last three years with zero look-ahead.
PVCT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 31% | 134 |
| 30-min | +0.01% | 50% | 162 |
| 60-min | +0.02% | 51% | 191 |
| to close | +0.47% | 58% | 218 |
| Middle 50% of PVCT reactions | -0.79% to +2.58% |
|---|---|
| Median reaction (30-min) | +0.01% |
| Measured reactions | 220 |
Half of all PROVECTUS BIOPHARMS news events land between -0.79% and +2.58% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when PVCT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PVCT's baseline. Nothing else.
Recent PVCT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 10-Q PROVECTUS BIOPHARMACEUTI For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | -3.61% | |
| VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase | Press release | GlobeNewswire | -0.52% | -0.04% | |
| Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose | Press release | GlobeNewswire | +0.00% | -1.82% | |
| Form 8-K PROVECTUS BIOPHARMACEUTI For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | -1.43% | -0.57% | |
| Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections | Press release | GlobeNewswire | +2.16% | +3.58% | |
| Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium) | Press release | GlobeNewswire | +1.25% | +2.06% | |
| Form 8-K PROVECTUS BIOPHARMACEUTI For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +1.64% | +7.87% | |
| Form 8-K PROVECTUS BIOPHARMACEUTI For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | — | +0.16% | |
| Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders | Press release | GlobeNewswire | +0.00% | +0.16% | |
| Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End | Press release | GlobeNewswire | +2.38% | +1.49% | |
| Form 10-Q PROVECTUS BIOPHARMACEUTI For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | +2.04% | |
| Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis | Press release | GlobeNewswire | +3.95% | +5.26% | |
| Form ARS PROVECTUS BIOPHARMACEUTI For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | — | +0.00% | |
| Form DEF 14A PROVECTUS BIOPHARMACEUTI For: Apr 30 | SEC filing · Form DEF | SEC EDGAR | — | +0.00% | |
| Form DEFA14A PROVECTUS BIOPHARMACEUTI | SEC filing · Form DEFA14A | SEC EDGAR | — | +0.00% | |
| Form 8-K PROVECTUS BIOPHARMACEUTI For: Apr 20 | SEC filing · Form 8-K | SEC EDGAR | -2.03% | -2.66% | |
| Form PRE 14A PROVECTUS BIOPHARMACEUTI For: Apr 20 | SEC filing · Form PRE | SEC EDGAR | +7.92% | +7.92% | |
| Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee | Press release | GlobeNewswire | -2.03% | -2.66% | |
| Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment | Press release | GlobeNewswire | +0.00% | -3.52% | |
| Form 10-K PROVECTUS BIOPHARMACEUTI For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -6.81% | |
| Form 8-K PROVECTUS BIOPHARMACEUTI For: Jan 30 | SEC filing · Form 8-K | SEC EDGAR | — | +0.00% | |
| Form 10-Q PROVECTUS BIOPHARMACEUTI For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy | Press release | GlobeNewswire | +0.00% | +5.83% | |
| Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer | Press release | GlobeNewswire | -10.48% | +0.00% | |
| Form 10-Q PROVECTUS BIOPHARMACEUTI For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | +0.00% | |
| Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer | Press release | GlobeNewswire | +0.00% | +7.02% | |
| Form 8-K PROVECTUS BIOPHARMACEUTI For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +0.76% | +1.84% | |
| Form 8-K PROVECTUS BIOPHARMACEUTI For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -7.15% | -3.00% | |
| Form DEFA14A PROVECTUS BIOPHARMACEUTI | SEC filing · Form DEFA14A | SEC EDGAR | -7.15% | -3.00% | |
| Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders | Press release | GlobeNewswire | +0.00% | -2.16% | |
| Form 10-K/A PROVECTUS BIOPHARMACEUTI For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | +1.17% | |
| Form 10-Q PROVECTUS BIOPHARMACEUTI For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.36% | |
| Form ARS PROVECTUS BIOPHARMACEUTI For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.11% | +7.64% | |
| Form DEF 14A PROVECTUS BIOPHARMACEUTI For: Apr 30 | SEC filing · Form DEF | SEC EDGAR | -0.11% | -0.77% | |
| Form DEFA14A PROVECTUS BIOPHARMACEUTI | SEC filing · Form DEFA14A | SEC EDGAR | -0.11% | -0.77% | |
| Form PRE 14A PROVECTUS BIOPHARMACEUTI For: Dec 31 | SEC filing · Form PRE | SEC EDGAR | -6.88% | -6.63% | |
| Form 8-K PROVECTUS BIOPHARMACEUTI For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | — | +2.78% | |
| Form 10-K PROVECTUS BIOPHARMACEUTI For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +5.31% | |
| Form 8-K PROVECTUS BIOPHARMACEUTI For: Jan 15 | SEC filing · Form 8-K | SEC EDGAR | — | +0.62% | |
| Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs | Press release | GlobeNewswire | +0.00% | +0.37% | |
| Form 8-K PROVECTUS BIOPHARMACEUTI For: Dec 20 | SEC filing · Form 8-K | SEC EDGAR | +0.26% | +4.18% | |
| Form 8-K PROVECTUS BIOPHARMACEUTI For: Dec 05 | SEC filing · Form 8-K | SEC EDGAR | -2.06% | +0.46% | |
| Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology | Press release | GlobeNewswire | -2.06% | +0.46% | |
| VisiRose Introduces Revolutionary Therapy for Severe Eye Infections | Press release | Accesswire | +0.00% | -17.86% | |
| Form 8-K PROVECTUS BIOPHARMACEUTI For: Dec 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +12.34% | |
| Form 8-K PROVECTUS BIOPHARMACEUTI For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | -0.18% | -0.63% | |
| Form 10-Q PROVECTUS BIOPHARMACEUTI For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | — | +2.02% | |
| Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference Call | Press release | GlobeNewswire | +0.65% | +0.23% | |
| Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call | Press release | GlobeNewswire | +0.00% | -4.70% | |
| Form 8-K PROVECTUS BIOPHARMACEUTI For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | — | +0.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PVCT section they belong to.
Where else PVCT is measured.
PVCT earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| INNOVATE BIOPHARMACEUTICALS (INNT) | 220 | -0.77% | 38% |
| OWC PHARMS RESEARCH CORP (OWCP) | 220 | +0.09% | 52% |
| TG Therapeutics, Inc. (TGTX) | 220 | -0.06% | 47% |
| Lipocine Inc. (LPCN) | 219 | +0.34% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is PROVECTUS BIOPHARMS's median reaction calculated?
Every labeled PVCT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 220 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of PVCT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PVCT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.